These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 8069732)
1. Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis. Lai PC; Wu MS; Huang JY; Huang CC; Leu ML Changgeng Yi Xue Za Zhi; 1994 Jun; 17(2):105-12. PubMed ID: 8069732 [TBL] [Abstract][Full Text] [Related]
2. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency. Raja R; Bloom E; Johnson R; Goldstein M Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811 [TBL] [Abstract][Full Text] [Related]
3. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Pais MJ; Gaspar A; Santana A; Bruges M; Simões J Perit Dial Int; 1993; 13 Suppl 2():S541-3. PubMed ID: 8399660 [TBL] [Abstract][Full Text] [Related]
4. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients. Raja R; Bloom E; Johnson R Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918 [TBL] [Abstract][Full Text] [Related]
5. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Eidemak I; Friedberg MO; Ladefoged SD; Løkkegaard H; Pedersen E; Skielboe M Nephrol Dial Transplant; 1992; 7(6):526-9. PubMed ID: 1320232 [TBL] [Abstract][Full Text] [Related]
6. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population. Raja R; Bloom E; Goldstein M; Johnson R ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603 [TBL] [Abstract][Full Text] [Related]
7. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. Besarab A; Golper TA ASAIO Trans; 1991; 37(3):M395-6. PubMed ID: 1751205 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Stockenhuber F; Loibl U; Gottsauner-Wolf M; Jahn C; Manker W; Meisl TF; Balcke P Nephron; 1991; 59(3):399-402. PubMed ID: 1758528 [TBL] [Abstract][Full Text] [Related]
9. [Maintenance therapy on the anemia in continuous ambulatory peritoneal dialysis (CAPD) patients using subcutaneous administration of recombinant human erythropoietin fortnightly--a multicenter trial]. Kubota M; Kawaguchi Y; Nomoto Y; Tsuchida H; Nihei H; Kubo K; Omori Y; Babazono T; Ogura Y; Hara S Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1081-90. PubMed ID: 8230819 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD. Icardi A; Paoletti E; Molinelli G Adv Perit Dial; 1990; 6():292-5. PubMed ID: 1982830 [TBL] [Abstract][Full Text] [Related]
11. The effect of subcutaneous recombinant human erythropoietin (r-Hu EPO) in CAPD patients with renal anaemia. Janicka L; Ksiazek A; Baranowicz I; Mierzicki P Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():67-77. PubMed ID: 8192534 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of renal anemia with intravenous erythropoietin in patients in the program of continuous ambulatory peritoneal dialysis]. Zelichowski G; Lubas A; Sienkiewicz M; Janusz E; Wańkowicz Z Pol Merkur Lekarski; 2008 Apr; 24(142):312-5. PubMed ID: 18634362 [TBL] [Abstract][Full Text] [Related]
13. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients. Trakarnvanich T; Thitiarcharkul S J Med Assoc Thai; 2004 Sep; 87(9):1041-7. PubMed ID: 15516004 [TBL] [Abstract][Full Text] [Related]
14. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998 [TBL] [Abstract][Full Text] [Related]